Development of a novel in vitro model of Alzheimer´s disease and its application to high-throughput screening assays

Alzheimer’s disease is the leading neurodegenerative disorder worldwide and the most prevalent cause of dementia, accounting for 60 to80% of all cases. With an estimated 50 million individuals affected globally and the incidence projected to triple by 2050, AD represents a growing public health and...

Descripción completa

Detalles Bibliográficos
Autor: Barro Fernández, Mateo
Tipo de recurso: tesis doctoral
Fecha de publicación:2025
País:España
Institución:Universidad de Santiago de Compostela (USC)
Repositorio:Minerva. Repositorio Institucional de la Universidad de Santiago de Compostela
Idioma:inglés
OAI Identifier:oai:dnet:minerva_____::4b194e3b17c540b1ff6b693827320ae4
Acceso en línea:https://hdl.handle.net/10347/41595
Access Level:acceso abierto
Palabra clave:Alzheimer
in vitro
cell model
HTS
neuropharmacology
249001 Neurofisiología
320711 Neuropatología
id ES_ac41cd33debdc2c33fde6214d4df1c76
oai_identifier_str oai:dnet:minerva_____::4b194e3b17c540b1ff6b693827320ae4
network_acronym_str ES
network_name_str España
repository_id_str
spelling Development of a novel in vitro model of Alzheimer´s disease and its application to high-throughput screening assaysBarro Fernández, MateoAlzheimerin vitrocell modelHTSneuropharmacology249001 Neurofisiología320711 NeuropatologíaAlzheimer’s disease is the leading neurodegenerative disorder worldwide and the most prevalent cause of dementia, accounting for 60 to80% of all cases. With an estimated 50 million individuals affected globally and the incidence projected to triple by 2050, AD represents a growing public health and socioeconomic burden. A small percentage of AD cases ,1 to 5%, are familial in origin, caused by mutations in genes such as APP, PSEN1/2, and MAPT, which influence the amyloidogenic pathway or tau protein processing. Conversely, the sporadic form of AD, which constitutes the majority of cases, is linked to complex genetic and environmental interactions, including aging, previous pathologies, oxidative stress, and chronic inflammation. Alzheimer’s pathology is characterized by a progressive cognitive decline driven by the loss of synaptic integrity, neuronal death, and chronic neuroinflammation. These neurodegenerative changes and progression of the disease are underpinned by key hallmark features such as amyloid-beta and tau deposits.Loza García, María IsabelBrea Floriani, José ManuelUniversidade de Santiago de Compostela. Escola de Doutoramento Internacional (EDIUS)20252025-01-0120252025-01-01doctoral thesishttp://purl.org/coar/resource_type/c_db06info:eu-repo/semantics/doctoralThesisapplication/pdfhttps://hdl.handle.net/10347/41595reponame:Minerva. Repositorio Institucional de la Universidad de Santiago de Compostelainstname:Universidad de Santiago de Compostela (USC)Inglésengopen accesshttp://purl.org/coar/access_right/c_abf2Attribution-NonCommercial-NoDerivatives 4.0 Internationalhttp://creativecommons.org/licenses/by-nc-nd/4.0/info:eu-repo/semantics/openAccessoai:dnet:minerva_____::4b194e3b17c540b1ff6b693827320ae42026-06-15T12:47:27Z
dc.title.none.fl_str_mv Development of a novel in vitro model of Alzheimer´s disease and its application to high-throughput screening assays
title Development of a novel in vitro model of Alzheimer´s disease and its application to high-throughput screening assays
spellingShingle Development of a novel in vitro model of Alzheimer´s disease and its application to high-throughput screening assays
Barro Fernández, Mateo
Alzheimer
in vitro
cell model
HTS
neuropharmacology
249001 Neurofisiología
320711 Neuropatología
title_short Development of a novel in vitro model of Alzheimer´s disease and its application to high-throughput screening assays
title_full Development of a novel in vitro model of Alzheimer´s disease and its application to high-throughput screening assays
title_fullStr Development of a novel in vitro model of Alzheimer´s disease and its application to high-throughput screening assays
title_full_unstemmed Development of a novel in vitro model of Alzheimer´s disease and its application to high-throughput screening assays
title_sort Development of a novel in vitro model of Alzheimer´s disease and its application to high-throughput screening assays
dc.creator.none.fl_str_mv Barro Fernández, Mateo
author Barro Fernández, Mateo
author_facet Barro Fernández, Mateo
author_role author
dc.contributor.none.fl_str_mv Loza García, María Isabel
Brea Floriani, José Manuel
Universidade de Santiago de Compostela. Escola de Doutoramento Internacional (EDIUS)
dc.subject.none.fl_str_mv Alzheimer
in vitro
cell model
HTS
neuropharmacology
249001 Neurofisiología
320711 Neuropatología
topic Alzheimer
in vitro
cell model
HTS
neuropharmacology
249001 Neurofisiología
320711 Neuropatología
description Alzheimer’s disease is the leading neurodegenerative disorder worldwide and the most prevalent cause of dementia, accounting for 60 to80% of all cases. With an estimated 50 million individuals affected globally and the incidence projected to triple by 2050, AD represents a growing public health and socioeconomic burden. A small percentage of AD cases ,1 to 5%, are familial in origin, caused by mutations in genes such as APP, PSEN1/2, and MAPT, which influence the amyloidogenic pathway or tau protein processing. Conversely, the sporadic form of AD, which constitutes the majority of cases, is linked to complex genetic and environmental interactions, including aging, previous pathologies, oxidative stress, and chronic inflammation. Alzheimer’s pathology is characterized by a progressive cognitive decline driven by the loss of synaptic integrity, neuronal death, and chronic neuroinflammation. These neurodegenerative changes and progression of the disease are underpinned by key hallmark features such as amyloid-beta and tau deposits.
publishDate 2025
dc.date.none.fl_str_mv 2025
2025-01-01
2025
2025-01-01
dc.type.none.fl_str_mv doctoral thesis
http://purl.org/coar/resource_type/c_db06
dc.type.openaire.fl_str_mv info:eu-repo/semantics/doctoralThesis
format doctoralThesis
dc.identifier.none.fl_str_mv https://hdl.handle.net/10347/41595
url https://hdl.handle.net/10347/41595
dc.language.none.fl_str_mv Inglés
eng
language_invalid_str_mv Inglés
language eng
dc.rights.none.fl_str_mv open access
http://purl.org/coar/access_right/c_abf2
Attribution-NonCommercial-NoDerivatives 4.0 International
http://creativecommons.org/licenses/by-nc-nd/4.0/
dc.rights.openaire.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv open access
http://purl.org/coar/access_right/c_abf2
Attribution-NonCommercial-NoDerivatives 4.0 International
http://creativecommons.org/licenses/by-nc-nd/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.source.none.fl_str_mv reponame:Minerva. Repositorio Institucional de la Universidad de Santiago de Compostela
instname:Universidad de Santiago de Compostela (USC)
instname_str Universidad de Santiago de Compostela (USC)
reponame_str Minerva. Repositorio Institucional de la Universidad de Santiago de Compostela
collection Minerva. Repositorio Institucional de la Universidad de Santiago de Compostela
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869416339922223104
score 15,812455

Similares en LA Referencia